New Study:
Lived experience of GLP-1 medications

A new study published in Diabetes, Obesity and Metabolism sheds light on the lived experiences of 1,659 individuals using GLP-1 receptor agonists for weight loss in a virtual care setting. Led by Maneeha Naveed and colleagues, the research explores the motivators, barriers, and realities of GLP-1 treatment—offering a human-centred perspective on one of the most talked-about obesity interventions of recent years.

The study reveals that over half of participants had been trying to lose weight for more than a decade before turning to GLP-1 medications like semaglutide and tirzepatide. These drugs, originally developed for type 2 diabetes, have shown remarkable promise in appetite suppression and weight reduction. But the journey is far from straightforward.

Among the most common barriers to weight loss were entrenched eating habits, stress, and menopause—factors often overlooked in traditional weight management programmes. Motivators, on the other hand, centred on reducing health risks and improving body satisfaction. Interestingly, symptom relief and increased energy emerged as unique drivers for GLP-1 users, suggesting a shift in priorities from aesthetics to wellbeing.

The study also highlights the concept of “food noise”—persistent, intrusive thoughts about food—which GLP-1s appear to quieten. Participants reported feeling more in control of their eating, with improved satiety and reduced cravings. Yet, not all experiences were positive. Side effects, cost, and unmet expectations led many to discontinue treatment, with some switching providers or abandoning medication altogether.

Video diaries added emotional depth to the data, revealing how stigma and shame influenced decisions to hide medication use. While some saw GLP-1s as a tool to support lifestyle changes, others relied solely on the medication, fearing weight regain if they stopped.

The authors call for more personalised care, including behavioural support and stress management, to improve adherence and outcomes. With obesity increasingly recognised as a chronic condition, this study underscores the need for compassionate, tailored interventions that go beyond the prescription pad.

As GLP-1s continue to reshape the landscape of obesity treatment, understanding the human stories behind the statistics may be the key to lasting change.

References
Naveed M, Perez C, Ahmad E, Russell L, Lees Z, Maybury C. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab. 2025;27(7):3780–3788. doi:10.1111/dom.16405